BioNTech Investor Day Presentation Deck

TCR discovery platform for tumor- and patient-specific therapies Establish TCR platform in solid tumors • Technologic iterations. • Combination with other assets ● (e.g. RiboCytokines) Acquisitions: PRAME-TCR and PD1-41BB switch (Medigene, Feb 2022) TCR, T-cell receptor. • TCR warehouse: multiple TCRs to target one or more antigens ● Broad patient coverage ● Library-like approach adding new targets and HLA alleles Collaboration with Medigene R&D Individualized treatment • On-demand identification of neoepitopes, timely manufacturing of customized T cells Cell therapies Acquisition: Neoantigen TCR platform (KITE, Jul 2021) BIONTECH 141

View entire presentation